Unlock this StockReport nowClick to Unlock

Orphazyme A/S Share Price

ORPHA DKK66.2 1.2  1.9%

Relative Strength (%)
Volume Change (%)
10d v 3m
Price vs... (%)
52w High
50d MA
200d MA
Growth & Value
Margin of Safety (beta)
Screens Passed
Balance Sheet · Income Statement · Cashflow Financial Summary
Year End 31st Dec 2013 2014 2015 2016 2017 2018 2019E 2020E CAGR / Avg
Revenue DKKm
Operating Profit DKKm
Net Profit DKKm
EPS Reported DKK
EPS Normalised DKK
EPS Growth %
PE Ratio x
Operating Margin %
Op. Cashflow ps DKK
Capex ps DKK
Free Cashflow ps DKK
Dividend ps DKK
Dividend Growth %
Dividend Yield %
Dividend Cover x
Balance Sheet
Cash etc DKKm
Working Capital DKKm
Net Fixed Assets DKKm
Net Debt DKKm
Book Value DKKm
Average Shares m
Book Value ps DKK +44.3%

FINANCIAL BRIEF: For the fiscal year ended 31 December 2018, Orphazyme A/S revenues was not reported. Net loss increased 82% to DKR229.6M. Higher net loss reflects Research & Development Expense increase of 99% to DKR195.9M (expense), Labor & Related Expenses in SGA increase from DKR7M to DKR15.8M (expense), Foreign Exchange Loss - Non-Business increase from DKR0K to DKR3.5M (expense). more »

Health Trend
Bankruptcy Risk
  Earnings Manipulation Risk
Magic Formula Score
Other Ratios
Leverage (ttm) Total -Intang +Pension
Gross Gearing %
Net Gearing %
Cash / Assets %
Recent History
Latest interim period (ended 31st Dec '18) vs. prior year
Sales Growth %
EPS Growth %
3yr Compound Annual Growth Rate
Sales Growth %
EPS Growth %
DPS Growth %

Broker Forecasts
31st Dec 2019
31st Dec 2020

Price Target: DKK119.8
(+84.21% above Price)
Net Profit EPS DPS Net Profit EPS DPS
Est. Long Term Growth Rate: n/a (DKK) (DKK) (DKK) (DKK) (DKK) (DKK)
Consensus Estimate
1m Change
3m Change
4 brokers Broker Consensus Trend
Broker Recommendations for Orphazyme A/S
Recommendation:Strong SellSellHoldBuyStrong Buy
No. of Analysts: 0 0 0 2 1

Named Brokers and Analysts
Danske Markets Thomas Bowers , Carnegie Investment Bank AB Jacob Lademann , Redeye Anders Hedlund , ODDO BHF Pierre Corby ,

Profile Summary

Orphazyme A/S, formerly Orphazyme ApS, is a Denmark-based company active within the biopharmaceutical industry. It develops new therapies for the treatment of a family of genetic disorders. The Company's main focus is on preclinical development of medicines for the treatment of lysosomal storage diseases (LSDs), a group of approximately 50 genetic disorders that result from deficiencies of lysosomal enzymes or other lysosomal components, and protein aggregation diseases. The Company’s candidate, arimoclomol, stimulates the production of the cells’ protein rescue system, the heat shock proteins, which helps the misfolded proteins to either get back to their functional shape or, if this cannot be achieved, remove them from the cells by means of the cells’ recycling system, the lysosomes, so they no longer form toxic aggregates. The Company collaborates with academic institutions in Europe and the United States.

Directors: Georges Gemayel (CHM) 59, Anders Moerkeberg Hinsby (CEO) , Bo Hansen (VCH) 61, Anders Fink Vadsholt (CFO) 47, Thomas Kirkegaard Jensen (CSO) , Thomas Blaettler (OTH) , Martin Bonde (DRC) , Remi Droller (DRC) 40, Anders Hedegaard (DRC) 58, Martijn Kleijwegt (DRC) 62, Catherine Moukheibir (DRC) 59,

No. of Employees: 57 No. of Shareholders: n/a

Last Annual December 31st, 2018
Last Interim January 1st, 1970
Incorporated June 19, 2009
Public Since November 17, 2017
Shares in Issue 19,984,799
Free Float 20.0m (100.0%)
Sector Healthcare
Industry Biotechnology & Medical Research
Exchange OMX Nordic Exchange - Copenhagen
Eligible for an ISA? a SIPP?

Address Ole Maaloees Vej 3 Copenhagen N, KOEBENHAVN, 2200, Denmark
Web https://www.orphazyme.com/
Phone +
Contact ()
Auditors Ernst & Young Godkendt Revisionspartnerselskab

ORPHA Share Price Performance ORPHA Share Price Quote
1.2  1.9%
Traded 3:15pm · Minimum 15 min delayed · NMS:

Latest ORPHA News Announcements (delayed)

Upcoming ORPHA Events
Wednesday 28th August, 2019
Interim Q2 2019 Orphazyme A/S Earnings Release

Recent ↓
Wednesday 27th March, 2019
Orphazyme A/S Annual Shareholders Meeting
Tuesday 12th March, 2019
Orphazyme A/S at Cowen Health Care Conference
Friday 1st March, 2019
Full Year 2018 Orphazyme A/S Earnings Release
Friday 1st March, 2019
Full Year 2018 Orphazyme A/S Earnings Call
Wednesday 30th January, 2019
Orphazyme A/S - Special Call
Friday 28th September, 2018
Orphazyme A/S - Special Call
Tuesday 28th August, 2018
Q2 2018 Orphazyme A/S Earnings Release
Tuesday 28th August, 2018
Q2 2018 Orphazyme A/S Earnings Call
Tuesday 29th May, 2018
Orphazyme A/S Capital Markets Day
Thursday 12th April, 2018
Orphazyme A/S Annual Shareholders Meeting

Use of our data service is subject to express Terms of Service. Please see our full site disclaimer for more details. In particular, it is very important to do your own research (DYOR) and seek professional advice before making any investment based on your own personal circumstances. Please note that the information, data and analysis contained within this stock report: (a) include the proprietary information of Stockopedia's third party licensors and Stockopedia; (b) should not be copied or redistributed except as specifically authorised; and (c) are not warranted to be complete, accurate or timely. You should independently research and verify any information that you find in this report. Stockopedia will not be liable in respect of any loss, trading or otherwise, that you may suffer arising out of such information or any reliance you may place upon it. Past performance is no guarantee of future results. The value and income derived from investments may go down as well as up. © Stockopedia 2019.

Should you buy ORPHA

Access ORPHA Analytics Now!

Let’s get you setup so you get the most out of our service
Done, Let's add some stocks
Brilliant - You've created a folio! Now let's add some stocks to it.

  • Apple (AAPL)

  • Shell (RDSA)

  • Twitter (TWTR)

  • Volkswagon AG (VOK)

  • McDonalds (MCD)

  • Vodafone (VOD)

  • Barratt Homes (BDEV)

  • Microsoft (MSFT)

  • Tesco (TSCO)
Save and show me my analysis